CANF
Price
$4.15
Change
+$0.11 (+2.72%)
Updated
Feb 5, 02:12 PM (EDT)
Capitalization
5.58M
Intraday BUY SELL Signals
PMN
Price
$15.65
Change
-$0.25 (-1.57%)
Updated
Feb 4 closing price
Capitalization
34.44M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs PMN

Header iconCANF vs PMN Comparison
Open Charts CANF vs PMNBanner chart's image
Can-Fite Biopharma
Price$4.15
Change+$0.11 (+2.72%)
Volume$1.2K
Capitalization5.58M
Promis Neurosciences
Price$15.65
Change-$0.25 (-1.57%)
Volume$47.97K
Capitalization34.44M
CANF vs PMN Comparison Chart in %
CANF
Daily Signal:
Gain/Loss:
PMN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CANF vs. PMN commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and PMN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (CANF: $4.04 vs. PMN: $15.65)
Brand notoriety: CANF and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 6% vs. PMN: 23%
Market capitalization -- CANF: $5.58M vs. PMN: $34.44M
CANF [@Biotechnology] is valued at $5.58M. PMN’s [@Biotechnology] market capitalization is $34.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CANF and PMN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 4 TA indicator(s) are bullish while PMN’s TA Score has 6 bullish TA indicator(s).

  • CANF’s TA Score: 4 bullish, 3 bearish.
  • PMN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PMN is a better buy in the short-term than CANF.

Price Growth

CANF (@Biotechnology) experienced а -8.80% price change this week, while PMN (@Biotechnology) price change was +29.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

PMN is expected to report earnings on Apr 06, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PMN($34.4M) has a higher market cap than CANF($5.58M). PMN YTD gains are higher at: 129.304 vs. CANF (1.000). CANF has higher annual earnings (EBITDA): -8.91M vs. PMN (-29.28M). PMN has more cash in the bank: 15.4M vs. CANF (995K). CANF has less debt than PMN: CANF (90K) vs PMN (4.05M). CANF has higher revenues than PMN: CANF (560K) vs PMN (0).
CANFPMNCANF / PMN
Capitalization5.58M34.4M16%
EBITDA-8.91M-29.28M30%
Gain YTD1.000129.3041%
P/E RatioN/A7.78-
Revenue560K0-
Total Cash995K15.4M6%
Total Debt90K4.05M2%
FUNDAMENTALS RATINGS
CANF vs PMN: Fundamental Ratings
CANF
PMN
OUTLOOK RATING
1..100
233
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9336
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (17) in the Biotechnology industry is significantly better than the same rating for PMN (92) in the null industry. This means that CANF’s stock grew significantly faster than PMN’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PMN (100) in the null industry. This means that CANF’s stock grew similarly to PMN’s over the last 12 months.

CANF's SMR Rating (100) in the Biotechnology industry is in the same range as PMN (100) in the null industry. This means that CANF’s stock grew similarly to PMN’s over the last 12 months.

PMN's Price Growth Rating (36) in the null industry is somewhat better than the same rating for CANF (93) in the Biotechnology industry. This means that PMN’s stock grew somewhat faster than CANF’s over the last 12 months.

PMN's P/E Growth Rating (99) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that PMN’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFPMN
RSI
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 23 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signal:
Gain/Loss:
PMN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HPQ19.820.82
+4.32%
HP
ZEUS52.170.68
+1.32%
Olympic Steel
TVTX31.68-1.16
-3.53%
Travere Therapeutics
OPXS14.56-0.63
-4.15%
Optex Systems Holdings
ACXP2.10-0.18
-7.89%
Acurx Pharmaceuticals

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been closely correlated with ACET. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.25%
ACET - CANF
87%
Closely correlated
-3.51%
STRO - CANF
87%
Closely correlated
+0.40%
PMN - CANF
87%
Closely correlated
-1.57%
ATOS - CANF
86%
Closely correlated
-4.34%
PHGE - CANF
86%
Closely correlated
-7.36%
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been closely correlated with ACET. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if PMN jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-1.57%
ACET - PMN
88%
Closely correlated
-3.51%
ATOS - PMN
87%
Closely correlated
-4.34%
CANF - PMN
87%
Closely correlated
-0.25%
STRO - PMN
87%
Closely correlated
+0.40%
PRAX - PMN
86%
Closely correlated
-2.31%
More